Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYNK-001 and rhIL-2 in Recurrent Glioblastoma
NCT05218408Phase 2Withdrawn
- Sponsor
- Celularity Inc.
- Start
- Sep 2021
- Primary completion
- Oct 2021
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
A Phase 2 trial of CYNK-001 in glioblastoma (GBM), sponsored by Celularity Inc.. Planned start Sep 2021; status: withdrawn.
02
Drugs
CYNK-001
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05218408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05218408.